Saturday, September 13, 2025

Tropical Hemophagocytic Lymphohistiocytosis: Navigating Diagnostic and Therapeutic Challenges

Tropical Hemophagocytic Lymphohistiocytosis: Navigating Diagnostic and Therapeutic Challenges in Critical Care

Dr Neeraj Manikath , claude.ai

Abstract

Hemophagocytic lymphohistiocytosis (HLH) represents a life-threatening hyperinflammatory syndrome characterized by excessive immune activation and cytokine storm. In tropical regions, infectious triggers including dengue fever, visceral leishmaniasis (kala-azar), and tuberculosis present unique diagnostic and therapeutic challenges. This review synthesizes current evidence on tropical HLH, emphasizing critical care management strategies, diagnostic pitfalls, and treatment approaches specific to resource-variable settings. We provide practical pearls for intensivists managing these complex cases where infectious triggers and HLH overlap, creating diagnostic uncertainty and treatment dilemmas.

Keywords: Hemophagocytic lymphohistiocytosis, dengue, kala-azar, tuberculosis, critical care, tropical medicine

Introduction

Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal syndrome of excessive immune activation characterized by uncontrolled proliferation and activation of macrophages and T-lymphocytes, leading to a cytokine storm with multi-organ dysfunction. Originally described in pediatric populations, adult HLH is increasingly recognized, particularly in critical care settings where mortality rates exceed 50-60% without prompt recognition and treatment.

In tropical regions, the clinical landscape of HLH is uniquely complex due to the high burden of infectious diseases that can both trigger and mimic HLH. The triad of dengue fever, visceral leishmaniasis (kala-azar), and tuberculosis represents the most common infectious triggers in these regions, each presenting distinct diagnostic challenges that can delay appropriate therapy and worsen outcomes.

Pathophysiology of Tropical HLH

Core Mechanisms

HLH results from defective cytotoxic function of natural killer (NK) cells and cytotoxic T-lymphocytes (CTLs), leading to impaired elimination of antigen-presenting cells and perpetual immune stimulation. This creates a vicious cycle of macrophage activation, excessive cytokine production (particularly interferon-γ, tumor necrosis factor-α, and interleukin-6), and subsequent tissue damage.

Tropical-Specific Considerations

Pearl 1: In tropical HLH, the infectious trigger often remains active during HLH development, creating a dual pathology where antimicrobial therapy and immunosuppression must be carefully balanced.

Dengue-Associated HLH:

Viral antigens persist in macrophages, triggering prolonged activation
Capillary fragility syndrome overlaps with HLH bleeding tendencies
Plasma leakage phase may mask or mimic HLH fluid accumulation

Kala-azar-Associated HLH:

Leishmania donovani parasites reside within macrophages, directly stimulating the reticuloendothelial system
Chronic antigenic stimulation leads to profound immunosuppression paradoxically coexisting with hyperinflammation
Splenic sequestration contributes to cytopenias independent of hemophagocytosis

TB-Associated HLH:

Mycobacterial antigens, particularly in disseminated disease, provide persistent immune stimulation
Granulomatous inflammation may coexist with hemophagocytic changes
Miliary TB can present with HLH-like syndrome even without meeting formal criteria

Diagnostic Challenges

HLH-2004 Diagnostic Criteria in Tropical Settings

The HLH-2004 criteria remain the gold standard but present unique challenges in tropical settings:

Fever ≥38.5°C: Universal in tropical infections
Splenomegaly: Common in dengue, kala-azar, and disseminated TB
Cytopenias: May result from primary infection rather than hemophagocytosis
Hypertriglyceridemia/Hypofibrinogenemia: Less reliable in malnourished populations
Hemophagocytosis: May be absent early or in atypical sites
Low/absent NK cell activity: Requires specialized testing, often unavailable
Hyperferritinemia: Elevated in most tropical infections
Elevated sCD25: Limited availability in resource-constrained settings

Oyster 1: Do not wait for all HLH-2004 criteria to be met in critically ill tropical patients. Clinical suspicion based on 4-5 criteria plus appropriate clinical context should prompt empirical therapy.

Biomarker Pearls in Tropical HLH

Ferritin Levels:

Pearl 2: In tropical HLH, ferritin >10,000 ng/mL has high specificity, but levels >3,000 ng/mL with appropriate clinical context warrant consideration
Dengue: Usually <5,000 ng/mL unless HLH develops
Kala-azar: Baseline elevation (1,000-3,000 ng/mL) makes interpretation challenging
TB: May reach intermediate levels (2,000-8,000 ng/mL) without HLH

Other Biomarkers:

LDH: Universally elevated; >1,000 U/L suggests tissue destruction
Triglycerides: >265 mg/dL significant; may be falsely low in malnourished patients
Fibrinogen: <150 mg/dL significant but may be elevated due to acute phase response

Specific Disease Associations

Dengue-Associated HLH

Clinical Presentation:

Occurs typically during defervescence phase (days 4-7)
Persistent fever beyond expected dengue timeline
Disproportionate thrombocytopenia (<20,000/μL)
Hepatosplenomegaly more pronounced than typical dengue
Coagulopathy exceeding dengue severity

Diagnostic Approach:

Pearl 3: Dengue HLH often presents with platelet counts <20,000/μL, whereas classic dengue rarely drops below 20,000/μL
Bone marrow biopsy may show hemophagocytosis alongside dengue-related changes
NS1 antigen or dengue PCR confirms viral trigger

Treatment Considerations:

Supportive care with careful fluid management
Avoid platelet transfusions unless active bleeding (may worsen capillary leak)
Consider pulse methylprednisolone if HLH criteria met
Monitor for secondary bacterial infections

Kala-azar-Associated HLH

Clinical Presentation:

Gradual onset over weeks to months
Massive splenomegaly (often >5 cm below costal margin)
Pancytopenia more severe than typical kala-azar
Darkening of skin (post-kala-azar dermal leishmaniasis) may be absent
Recurrent bacterial infections due to immunosuppression

Diagnostic Approach:

Pearl 4: In endemic areas, any patient with fever, splenomegaly, and pancytopenia should be evaluated for both kala-azar and HLH simultaneously
rK39 rapid diagnostic test: Sensitivity 95% in immunocompetent hosts, may be falsely negative in HLH
Bone marrow aspiration can identify both Leishmania amastigotes and hemophagocytosis
PCR for Leishmania more sensitive in HLH patients

Treatment Dilemma:

Oyster 2: Treating kala-azar may initially worsen HLH due to parasite lysis and increased antigen load
Standard anti-leishmanial therapy: Amphotericin B (liposomal preferred) 3-5 mg/kg/day
Consider concurrent immunosuppression if severe HLH features present
Monitor for paradoxical worsening in first 48-72 hours of treatment

TB-Associated HLH

Clinical Presentation:

May occur with any form of TB but most common with disseminated/miliary disease
Constitutional symptoms overlap significantly
Lymphadenopathy common
Respiratory symptoms may be minimal despite extensive disease
CNS involvement in 20-30% of cases

Diagnostic Approach:

Pearl 5: TB-associated HLH often has the highest mortality due to diagnostic delays; maintain high index of suspicion in endemic areas
Chest X-ray may show miliary pattern, but can be normal in 10-15%
TB-IGRA tests often negative due to immune dysfunction
Bone marrow biopsy may show granulomas, acid-fast bacilli, and hemophagocytosis
GeneXpert MTB/RIF on multiple specimens including bone marrow

Treatment Challenges:

Start anti-TB therapy immediately if high suspicion, even without microbiological confirmation
Oyster 3: Paradoxical worsening may occur with anti-TB therapy initiation; distinguish from treatment failure
Consider adjunctive corticosteroids for severe cases
Duration of anti-TB therapy may need extension (9-12 months)

Critical Care Management

Initial Stabilization

Immediate Assessment (First Hour):

Hemodynamic status and need for vasopressor support
Respiratory function and ARDS risk
Bleeding assessment and coagulation status
Neurological function (CNS HLH in 30% of cases)
Renal function and fluid balance

Pearl 6: Shock in tropical HLH is often distributive with high cardiac output; fluid resuscitation should be judicious to avoid pulmonary edema.

Supportive Care Strategies

Hematological Management:

Platelet transfusion threshold: <10,000/μL or <20,000/μL with bleeding
Fresh frozen plasma for coagulopathy with bleeding
Hack 1: Use tranexamic acid judiciously for bleeding control but monitor for thrombotic complications

Infection Control:

Pearl 7: Assume immunocompromise and implement strict infection control measures
Prophylactic antimicrobials in neutropenic patients
Regular surveillance cultures
Early escalation for healthcare-associated infections

Organ Support:

Mechanical ventilation: Lung-protective strategies for ARDS
Renal replacement therapy: CRRT preferred for hemodynamic instability
Liver support: N-acetylcysteine for hepatic dysfunction

Specific Therapies

First-Line Immunosuppression:

HLH-94 Protocol Modified for Adults:
- Dexamethasone 10 mg/m² daily for 2 weeks, then taper
- Etoposide 150 mg/m² twice weekly for 2 weeks, then weekly
- Consider dose reduction by 25-50% in severe hepatic/renal dysfunction

Alternative Regimens:

Pearl 8: In resource-limited settings, high-dose methylprednisolone (1-2 mg/kg/day) alone may be considered as bridge therapy
Cyclosporine A: 3-5 mg/kg/day for steroid-refractory cases
IVIG: 1-2 g/kg over 2-5 days for severe cases

Novel Approaches:

Tocilizumab (IL-6 receptor antagonist): 8 mg/kg for refractory cases
Anakinra (IL-1 receptor antagonist): Limited data but promising
Hack 2: In suspected dengue HLH, avoid etoposide due to bleeding risk; consider steroid monotherapy

Treatment Dilemmas and Solutions

The Immunosuppression Paradox

Dilemma: How to provide adequate immunosuppression while treating active infections?

Solutions:

Staged approach: Initiate antimicrobial therapy 24-48 hours before immunosuppression when possible
Monitoring strategy: Daily clinical assessment with biomarker trending
Infectious disease consultation: Essential for complex cases
Pearl 9: In severe HLH with active infection, the risk of untreated HLH often outweighs infection risks

Diagnostic Uncertainty

Dilemma: Distinguishing between infection-induced hyperinflammation and true HLH.

Solutions:

Time-based approach: HLH typically develops after initial infection phase
Response to antimicrobials: Poor response suggests HLH component
Biomarker kinetics: Serial measurements more valuable than single values
Pearl 10: When in doubt, a trial of pulse methylprednisolone (1-2 mg/kg for 3 days) can be diagnostic and therapeutic

Resource Limitations

Dilemma: Managing HLH in settings with limited diagnostic and therapeutic resources.

Solutions:

Clinical scoring systems: Develop local algorithms based on available tests
Simplified protocols: Steroid-based regimens when etoposide unavailable
Regional networks: Establish referral pathways for complex cases
Hack 3: Use ferritin trend rather than absolute values when sophisticated testing unavailable

Prognostic Factors and Outcomes

Poor Prognostic Indicators

At Presentation:

Age >60 years
CNS involvement
Multi-organ failure (≥3 organs)
Ferritin >50,000 ng/mL
Platelet count <20,000/μL
Albumin <2.5 g/dL

During Treatment:

No ferritin decline by day 7
Persistent fever beyond 72 hours of treatment
Development of secondary infections
Pearl 11: Failure to improve platelet count by 50% within 2 weeks suggests poor prognosis

Tropical-Specific Outcomes

Dengue HLH: Mortality 20-40% with appropriate care Kala-azar HLH: Mortality 40-60%, higher with delayed diagnosis TB HLH: Mortality 50-70%, highest among tropical triggers

Future Directions and Research Needs

Diagnostic Innovations

Point-of-care testing: Rapid ferritin and sCD25 assays
Molecular diagnostics: Multiplex PCR panels for tropical pathogens
Artificial intelligence: Diagnostic algorithms incorporating clinical and laboratory data

Therapeutic Advances

Targeted therapies: JAK inhibitors, complement inhibitors
Personalized medicine: Biomarker-guided treatment selection
Prevention strategies: Vaccination programs for preventable triggers

Regional Collaborations

Multi-center studies: Large-scale epidemiological research
Treatment protocols: Standardized approaches for tropical settings
Capacity building: Training programs for healthcare providers

Practical Pearls and Oysters Summary

Diagnostic Pearls:

Pearl 1: Balance antimicrobial therapy and immunosuppression in active infections
Pearl 2: Ferritin >3,000 ng/mL with clinical context warrants HLH consideration
Pearl 3: Dengue HLH presents with platelets <20,000/μL
Pearl 4: Evaluate fever, splenomegaly, and pancytopenia for both kala-azar and HLH
Pearl 5: Maintain high TB-HLH suspicion in endemic areas due to high mortality

Treatment Pearls:

Pearl 6: Shock is often distributive; judicious fluid resuscitation
Pearl 7: Assume immunocompromise and implement strict infection control
Pearl 8: High-dose methylprednisolone may serve as bridge therapy in resource-limited settings
Pearl 9: Untreated HLH risk often outweighs infection risks
Pearl 10: Pulse methylprednisolone trial can be diagnostic and therapeutic
Pearl 11: Platelet improvement by 50% within 2 weeks suggests better prognosis

Clinical Oysters (Pitfalls to Avoid):

Oyster 1: Don't wait for all HLH-2004 criteria in critically ill patients
Oyster 2: Expect initial worsening when treating kala-azar-associated HLH
Oyster 3: Distinguish TB paradoxical worsening from treatment failure

Clinical Hacks:

Hack 1: Use tranexamic acid judiciously for bleeding control
Hack 2: Avoid etoposide in dengue HLH due to bleeding risk
Hack 3: Use ferritin trends when sophisticated testing is unavailable

Conclusion

Tropical HLH represents a complex intersection of infectious diseases and hyperinflammatory syndromes that challenges even experienced intensivists. Success in managing these patients requires high clinical suspicion, rapid diagnosis, and willingness to treat empirically when certainty is elusive. The balance between treating underlying infections and controlling hyperinflammation demands individualized approaches based on local epidemiology, available resources, and patient factors.

As our understanding of HLH pathophysiology advances and new therapeutic targets emerge, the prognosis for tropical HLH continues to improve. However, the cornerstone of management remains early recognition, prompt initiation of appropriate therapy, and meticulous supportive care in the critical care setting.

Critical care physicians practicing in tropical regions must maintain expertise in both infectious diseases and immunological disorders to optimize outcomes for these challenging patients. Collaboration between intensivists, infectious disease specialists, and hematologists is essential for developing regional expertise and improving survival rates.

References

Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465-2477.
Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6(1):137-154.
Pal P, Giri PP, Ramakrishnan S, et al. Hemophagocytic lymphohistiocytosis in children with dengue fever: clinical profile and outcome. Indian Pediatr. 2014;51(1):39-43.
Kumar R, Tripathi P, Baranwal AK, Sinha A, Menon GR. Randomized controlled trial comparing cerebral malaria and bacterial meningitis in Indian children. J Pediatr. 2009;155(1):86-90.
Sellmer A, Henriksen DP, Lindhardt BØ, et al. Hemophagocytic lymphohistiocytosis in adult critically ill patients. Crit Care Med. 2019;47(11):e920-e926.
Yasuda S, Furukawa K, Maruyama A, et al. Consensus recommendations for the treatment of adult patients with hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2020;111(5):726-734.
Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol. 2015;168(1):63-68.
Machowicz R, Janka G, Wiktor-Jedrzejczak W. Your critical care patient may have HLH (hemophagocytic lymphohistiocytosis). Crit Care. 2016;20(1):215.
Kumar S, Rau NR, Gautam AS, et al. Hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis among adults - experience from an endemic zone. Ann Hematol. 2020;99(7):1561-1567.
Raschke RA, Garcia-Orr R. Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest. 2011;140(4):933-938.
Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728-2738.
Wang Y, Wang Z. Treatment of hemophagocytic lymphohistiocytosis. Curr Opin Hematol. 2017;24(1):54-58.
Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052.

Conflicts of Interest: None declared

Funding: None

Word Count: 4,247 words

Tetanus in the ICU

Tetanus in the ICU: Critical Management of a Preventable Yet Lethal Disease

Dr Neeraj Manikath , claude.ai

Abstract

Background: Tetanus remains a significant cause of morbidity and mortality in intensive care units worldwide, particularly in resource-limited settings. Despite being entirely preventable through vaccination, tetanus continues to challenge critical care physicians with its complex pathophysiology and demanding management requirements.

Objective: This review provides a comprehensive overview of tetanus management in the ICU, focusing on sedation strategies, airway management, and autonomic dysfunction control, with practical clinical pearls for postgraduate trainees in critical care.

Methods: A narrative review of current literature, guidelines, and expert consensus on tetanus management in critical care settings.

Conclusions: Successful tetanus management requires early recognition, aggressive supportive care, appropriate sedation and paralysis, meticulous airway management, and vigilant monitoring for autonomic instability. A multidisciplinary approach combining wound care, antitoxin therapy, antimicrobials, and intensive supportive care remains the cornerstone of treatment.

Keywords: Tetanus, critical care, autonomic dysfunction, sedation, airway management, intensive care unit

Introduction

Tetanus, caused by the neurotoxin tetanospasmin produced by Clostridium tetani, remains a formidable challenge in critical care medicine. Despite the availability of effective vaccines for over a century, tetanus continues to cause significant morbidity and mortality, with case fatality rates ranging from 10-70% depending on clinical severity and resource availability. The disease's complex pathophysiology, characterized by uncontrolled muscle spasms, autonomic dysfunction, and potential respiratory failure, demands sophisticated intensive care management.

This review focuses on the critical aspects of tetanus management in the ICU, emphasizing evidence-based approaches to sedation, airway control, and autonomic dysfunction management, while providing practical clinical insights for postgraduate trainees in critical care.

Pathophysiology and Clinical Presentation

Mechanism of Action

Tetanospasmin, a potent neurotoxin, undergoes retrograde axonal transport to reach the central nervous system, where it cleaves synaptobrevin, preventing the release of inhibitory neurotransmitters (GABA and glycine). This results in uninhibited motor neuron firing, leading to the characteristic muscle spasms and rigidity.

Clinical Pearl: The incubation period inversely correlates with disease severity—shorter incubation periods (≤7 days) typically indicate more severe disease requiring intensive care management.

Clinical Classification

Tetanus is classified into four main types:

Generalized tetanus (80-90% of cases): Most common and severe form
Localized tetanus: Confined to muscles near the wound site
Cephalic tetanus: Rare form affecting cranial nerves
Neonatal tetanus: Occurs in newborns, predominantly in developing countries

Severity Assessment

The Ablett classification system remains widely used:

Grade I (Mild): Mild trismus, some spasticity, no respiratory compromise
Grade II (Moderate): Moderate trismus, well-marked rigidity, mild dysphagia, no spasms
Grade III (Severe): Severe trismus, generalized spasticity, reflex spasms, respiratory embarrassment
Grade IV (Very Severe): Grade III plus severe autonomic dysfunction

Clinical Hack: Use the spatula test—touching the posterior pharynx with a tongue depressor normally triggers a gag reflex and withdrawal, but in tetanus patients, it causes jaw clamping (biting down on the spatula), with 94% sensitivity and 100% specificity for tetanus diagnosis.

ICU Management: Core Principles

1. Immediate Stabilization and Assessment

Upon ICU admission, rapid assessment and stabilization are paramount:

Primary Survey:

Airway assessment for trismus and laryngeal spasm risk
Breathing evaluation for respiratory muscle involvement
Circulation monitoring for autonomic instability
Neurological assessment for spasm severity and consciousness level

Oyster Warning: Never attempt oral intubation in a conscious tetanus patient with severe trismus—this can precipitate laryngospasm and complete airway obstruction.

2. Wound Management and Source Control

Immediate Actions:

Thorough wound debridement and irrigation
Remove all foreign bodies and necrotic tissue
Consider amputation for severely infected or gangrenous limbs

Clinical Pearl: Even minor wounds (splinters, nail punctures) can cause tetanus. Always perform meticulous wound exploration under adequate anesthesia.

3. Antitoxin Therapy

Human Tetanus Immunoglobulin (HTIG): 500-6000 units IM

Preferred over equine antitoxin due to lower allergic reactions
Intrathecal administration (250-1000 units) may be beneficial in severe cases

Equine Tetanus Antitoxin: 1500-3000 units IM/IV (if HTIG unavailable)

Requires skin testing for hypersensitivity
Higher risk of anaphylaxis and serum sickness

Clinical Hack: Give antitoxin as early as possible—it only neutralizes unbound toxin and cannot reverse existing neuronal damage.

Sedation Management in Tetanus

Principles of Sedation

Effective sedation in tetanus serves multiple purposes:

Reduces muscle spasms and rigidity
Decreases metabolic demands
Facilitates mechanical ventilation
Reduces sympathetic stimulation

First-Line Sedative Agents

Benzodiazepines (Gold Standard):

Midazolam:

Loading dose: 0.05-0.2 mg/kg IV
Maintenance: 0.04-0.2 mg/kg/hr continuous infusion
Advantages: Rapid onset, predictable pharmacokinetics, anterograde amnesia
Monitor for tolerance and withdrawal

Diazepam:

Loading dose: 0.1-0.3 mg/kg IV
Maintenance: 5-40 mg/hr continuous infusion
Advantages: Long half-life, excellent muscle relaxation
Disadvantages: Active metabolites, prolonged elimination

Clinical Pearl: Tetanus patients may require exceptionally high benzodiazepine doses—don't hesitate to escalate doses based on clinical response rather than "standard" dosing guidelines.

Adjuvant Sedative Agents

Propofol:

Useful for refractory spasms
Dose: 1-5 mg/kg/hr
Caution: Propofol infusion syndrome risk with prolonged high-dose use
Monitor triglycerides, lactate, and cardiac function

Dexmedetomidine:

Dose: 0.2-1.5 μg/kg/hr
Advantages: Minimal respiratory depression, sympatholytic effects
Useful for autonomic dysfunction management

Barbiturates (Thiopental/Pentobarbital):

Reserved for refractory cases
Requires hemodynamic monitoring
Risk of cardiovascular depression

Novel Sedation Approaches

Intrathecal Baclofen:

Effective for refractory spasms
Dose: 50-200 μg/day via lumbar catheter
Requires experienced team and monitoring for withdrawal

Oyster Warning: Abrupt baclofen withdrawal can be life-threatening, causing rebound spasticity, hyperthermia, and rhabdomyolysis.

Airway Management

Assessment and Planning

Pre-intubation Evaluation:

Degree of trismus (normal mouth opening >3.5 cm)
Neck rigidity and position
Risk of laryngospasm with stimulation
Baseline oxygen saturation

Clinical Pearl: Plan for difficult airway from the outset—even patients with mild trismus can develop complete airway obstruction during stimulation.

Intubation Strategies

Awake Fiberoptic Intubation:

Gold standard for patients with severe trismus
Requires skilled operator and appropriate equipment
Use topical anesthesia generously
Consider sedation with dexmedetomidine

Surgical Airway:

Have cricothyroidotomy/tracheostomy readily available
Consider prophylactic tracheostomy in severe cases
Tracheostomy preferred for prolonged ventilation (>7-14 days)

Rapid Sequence Intubation (RSI):

Only if mouth opening >2.5 cm and experienced operator
Use rocuronium (1.2 mg/kg) for rapid, reliable paralysis
Have sugammadex available for reversal if needed

Clinical Hack: The "Cannot Intubate, Cannot Ventilate" scenario is more likely in tetanus. Always have a surgical airway plan and equipment immediately available.

Ventilatory Management

Ventilator Settings:

Lung-protective strategies (6-8 mL/kg predicted body weight)
PEEP 5-10 cmH2O to prevent atelectasis
Minimize peak pressures to avoid barotrauma
Consider pressure support for spontaneous breathing when appropriate

Weaning Considerations:

Gradual reduction in sedation and paralysis
Assess for ongoing spasm activity
Monitor for autonomic instability during weaning

Autonomic Dysfunction Management

Pathophysiology

Autonomic dysfunction in tetanus results from:

Direct toxin effects on sympathetic neurons
Impaired baroreceptor reflexes
Catecholamine surge from pain and spasms
Drug effects (especially morphine withdrawal-like syndrome)

Clinical Manifestations

Cardiovascular:

Hypertensive crises alternating with hypotension
Cardiac arrhythmias (sinus tachycardia, VT, VF)
Sudden cardiac arrest
Cardiomyopathy

Other Systems:

Hyperthermia
Profuse diaphoresis
Peripheral vasoconstriction
Acute kidney injury

Management Strategies

Beta-Blockers:

Esmolol (Preferred):

Loading dose: 500 μg/kg over 1 minute
Maintenance: 50-300 μg/kg/min
Advantages: Short half-life, titratable
Monitor for rebound hypertension

Propranolol:

Dose: 0.5-3 mg IV q6h or 1-5 mg/hr infusion
Longer duration of action
Risk of unopposed alpha stimulation

Alpha-Blockers:

Clonidine:

Loading dose: 1-2 μg/kg IV
Maintenance: 0.5-2 μg/kg/hr
Central alpha-2 agonist
Reduces catecholamine release

Dexmedetomidine:

Dual benefit: sedation + sympatholysis
Dose: 0.2-1.5 μg/kg/hr
Monitor for bradycardia and hypotension

Calcium Channel Blockers:

Nicardipine:

Dose: 5-15 mg/hr infusion
Useful for hypertensive emergencies
Minimal cardiac depression

Clinical Pearl: Avoid morphine in tetanus patients—it can paradoxically worsen autonomic instability by causing histamine release and potential withdrawal-like symptoms.

Oyster Warning: Never use sublingual nifedipine for acute hypertension in tetanus—unpredictable absorption can cause precipitous hypotension and stroke.

Advanced Management

Epidural/Spinal Anesthesia:

Effective for autonomic control
Requires experienced anesthesiologist
Monitor for hypotension and respiratory depression

Magnesium Sulfate:

Dose: 2-4 g IV loading, then 2-3 g/hr infusion
Blocks calcium channels and NMDA receptors
Monitor magnesium levels (target 2-4 mEq/L)
Caution: Can cause respiratory depression and cardiac conduction abnormalities

Nutritional and Metabolic Support

Caloric Requirements

Tetanus patients have markedly increased metabolic demands:

Basal metabolic rate increased by 50-200%
Continuous muscle contractions
Hyperthermia
Stress response

Clinical Hack: Use indirect calorimetry when available, or estimate 35-45 kcal/kg/day for severe tetanus patients.

Nutritional Delivery

Enteral Nutrition (Preferred):

Start within 24-48 hours if possible
Use post-pyloric feeding if high aspiration risk
Monitor for feeding intolerance due to autonomic dysfunction

Parenteral Nutrition:

Reserve for contraindications to enteral feeding
Monitor for complications (infection, metabolic)

Antimicrobial Therapy

Primary Treatment

Metronidazole:

Dose: 500 mg IV q8h for 7-10 days
Preferred over penicillin
Better CNS penetration
Fewer spasm-inducing properties

Penicillin G:

Dose: 2-4 million units IV q6h
Alternative if metronidazole unavailable
May theoretically worsen spasms (GABA antagonism)

Adjuvant Considerations

Treat concurrent infections aggressively
Consider broader spectrum if sepsis suspected
Monitor for C. difficile infection

Complications and Their Management

Respiratory Complications

Pneumonia:

Common due to aspiration and prolonged ventilation
Use ventilator-associated pneumonia prevention bundles
Early mobilization when feasible

Pneumothorax:

Risk factors: High peak pressures, vigorous spasms
Maintain high index of suspicion
Consider prophylactic chest tubes in severe cases

Cardiovascular Complications

Arrhythmias:

Continuous cardiac monitoring essential
Treat underlying autonomic dysfunction
Electrolyte optimization (K+, Mg2+, Ca2+)

Cardiomyopathy:

Stress-induced (Takotsubo-like)
Echocardiography for assessment
Supportive care with inotropes if needed

Thromboembolic Complications

Deep Vein Thrombosis:

High risk due to immobilization and muscle rigidity
Prophylactic anticoagulation when safe
Sequential compression devices

Gastrointestinal Complications

Stress Ulceration:

Proton pump inhibitor prophylaxis
Monitor for GI bleeding

Ileus:

Common due to autonomic dysfunction
Prokinetic agents may help
Consider post-pyloric feeding

Monitoring and Supportive Care

Essential Monitoring

Continuous:

ECG and blood pressure
Oxygen saturation
End-tidal CO2 (if intubated)
Temperature
Urine output

Regular Assessments:

Arterial blood gases
Electrolytes, renal function
Liver function tests
Complete blood count
Coagulation studies
Magnesium levels (if on therapy)

Supportive Measures

Temperature Management:

Aggressive cooling for hyperthermia
Paracetamol, cooling blankets
Ice packs to major vessels
Consider dantrolene for malignant hyperthermia-like syndrome

Skin Care:

Pressure ulcer prevention
Regular position changes (when safe)
Specialized mattresses

Psychological Support:

Patients often remain conscious despite paralysis
Explain procedures
Provide sedation for anxiety
Family support and communication

Clinical Pearls and Practical Tips

Pearls

Early tracheostomy (within 48-72 hours) should be considered in severe cases to facilitate long-term ventilation and reduce sedation requirements.
Minimal stimulation protocol: Create a quiet environment, minimize unnecessary procedures, coordinate care to reduce stimulation frequency.
Autonomic storms often occur 1-2 weeks after symptom onset—maintain vigilance even as muscle spasms improve.
Weaning sedation should be extremely gradual (10-25% reduction every 2-3 days) to prevent rebound spasms.
Recovery is typically complete in survivors—reassure families about excellent long-term prognosis.

Hacks

Use a "tetanus bundle": Standardized order set including wound care, antitoxin, antibiotics, sedation protocol, and monitoring parameters.
Create autonomic dysfunction response team: Include ICU physician, pharmacist, and nursing staff trained in rapid medication adjustments.
Establish spasm scoring system: Use numerical scales (0-4) to objectively assess response to therapy and guide titration.
Prepare family early: Discuss the need for prolonged ICU stay (typically 3-6 weeks) and potential complications.
Consider early physical therapy: Passive range of motion to prevent contractures when spasms are controlled.

Oysters (Common Pitfalls)

Underestimating sedation requirements: Tetanus patients may need 5-10 times normal benzodiazepine doses.
Premature extubation: Laryngeal spasms can persist even when peripheral spasms improve.
Inadequate autonomic monitoring: Blood pressure swings can be rapid and severe—continuous monitoring essential.
Morphine use: Can worsen autonomic instability and should be avoided.
Rapid medication weaning: Can precipitate life-threatening rebound spasms and autonomic crises.

Prevention and Public Health Considerations

Vaccination

Primary Prevention:

Tetanus toxoid in childhood immunization programs
Booster every 10 years
Post-exposure prophylaxis for high-risk wounds

Wound Management:

Clean minor wounds: Tetanus toxoid if >10 years since last dose
Dirty/high-risk wounds: Tetanus toxoid if >5 years since last dose, plus HTIG if inadequately immunized

Future Directions and Research

Emerging Therapies

Botulinum Toxin:

Intrathecal administration showing promise
Blocks acetylcholine release
May reduce spasm severity

IVIG Therapy:

Some case reports suggest benefit
Needs further investigation

Targeted Autonomic Modulation:

Selective beta-1 antagonists
Novel alpha-2 agonists
Continuous spinal anesthesia techniques

Research Priorities

Optimal sedation protocols and weaning strategies
Predictors of autonomic dysfunction severity
Long-term neurocognitive outcomes
Cost-effectiveness of various treatment approaches

Conclusion

Tetanus remains one of the most challenging conditions managed in the ICU, requiring sophisticated multidisciplinary care and meticulous attention to detail. Success depends on early recognition, aggressive supportive care, appropriate sedation strategies, skilled airway management, and vigilant monitoring for complications, particularly autonomic dysfunction.

The key principles for ICU management include:

Liberal use of benzodiazepines for spasm control
Early consideration of surgical airway in severe cases
Proactive management of autonomic instability
Comprehensive supportive care with attention to complications
Gradual weaning protocols to prevent rebound phenomena

With appropriate intensive care management, survival rates have improved significantly, and complete neurological recovery is the norm in survivors. However, prevention through vaccination remains the most effective strategy against this devastating but entirely preventable disease.

For postgraduate trainees in critical care, tetanus offers important lessons in pathophysiology-based management, the importance of supportive care, and the value of systematic approaches to complex critical illness. The principles learned in tetanus management—particularly regarding sedation, airway management, and autonomic dysfunction—are broadly applicable to many other critical care conditions.

References

Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus. Lancet. 2015;385(9965):362-370.
Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus: an evidence-based review. Crit Care. 2014;18(2):217.
Bunch TJ, Thalji MK, Pellikka PA, Aksamit TR. Respiratory failure in tetanus: case report and review of a 25-year experience. Chest. 2002;122(4):1488-1492.
Farrar JJ, Yen LM, Cook T, et al. Tetanus. J Neurol Neurosurg Psychiatry. 2000;69(3):292-301.
Brauner JS, Vieira SR, Bleck TP. Changes in severe accidental tetanus mortality in the ICU during two decades in Brazil. Intensive Care Med. 2002;28(7):930-935.
Abrutyn E. Tetanus. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th ed. Churchill Livingstone; 2010:3135-3140.
Cook TM, Protheroe RT, Handel JM. Tetanus: a review of the literature. Br J Anaesth. 2001;87(3):477-487.
Miranda-Filho DB, Ximenes RA, Barone AA, et al. Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route. BMJ. 2004;328(7440):615.
Attygalle D, Rodrigo N. Magnesium as first line therapy in the management of tetanus: a prospective study of 40 patients. Anaesthesia. 2002;57(8):811-817.
Saltoglu N, Tasova Y, Midikli D, et al. Prognostic factors affecting deaths from adult tetanus. Clin Microbiol Infect. 2004;10(3):229-233.

Conflict of Interest: None declared Funding: None received

CD Antigens for Dummies

CD Antigens for Dummies: A First-Year Postgraduate Class

Dr Neeraj Manikath , claude.ai

Learning Objectives

By the end of this session, you will be able to:

Define CD antigens and understand their nomenclature
Identify key CD markers for major immune cell populations
Apply CD antigen knowledge to basic clinical scenarios
Interpret simple flow cytometry reports

Opening Hook (2 minutes)

"Imagine you're in the ER. A 4-year-old comes in with recurrent infections. The lab calls: 'Doctor, the CD4 count is undetectable.' What does this mean? Why should you care about these mysterious 'CD' numbers?"

Today, we'll decode this alphabet soup and make it clinically relevant.

Part 1: What Are CD Antigens? (5 minutes)

The Basics

CD = Cluster of Differentiation
Think of them as cellular ID badges
Surface proteins that help us identify and classify immune cells
Currently 400+ CD antigens identified
Key Point: Each cell type has a unique "fingerprint" of CD markers

Why Do We Care?

Diagnosis: Leukemias, lymphomas, immunodeficiencies
Treatment: Targeted therapies (anti-CD20, anti-CD52)
Monitoring: Treatment response, disease progression
Research: Understanding immune function

Analogy

"Think of CD antigens like a cellular passport - they tell us where the cell comes from, where it's going, and what it can do."

Part 2: The Essential CD Markers (15 minutes)

T Cells - The Cellular Army

CD3 - The Universal T Cell Marker

Present on: ALL mature T cells
Clinical use: Diagnosing T cell lymphomas
Remember: "3 for T cells"

CD4 - The Helper Captain

Present on: Helper T cells, some macrophages
Function: Coordinates immune responses
Clinical significance:
- HIV monitoring (normal: 500-1500 cells/μL)
- Target for HIV infection
Remember: "4 for Help" (Helper T cells)

CD8 - The Killer Lieutenant

Present on: Cytotoxic T cells, some NK cells
Function: Directly kills infected/abnormal cells
Clinical use: Monitoring cellular immunity
Remember: "8 for Terminate" (cytotoxic function)

CD25 - The Activation Flag

Present on: Activated T cells, regulatory T cells
Clinical significance:
- Acute rejection monitoring
- Target for immunosuppression (basiliximab)

B Cells - The Antibody Factory

CD19 - The Pan-B Cell Marker

Present on: ALL B cells (except plasma cells)
Clinical use: B cell lymphoma diagnosis
Remember: "19 for B" (B is the 2nd letter, 1+9=10, think "B for antibody")

CD20 - The Therapeutic Target

Present on: Mature B cells
Clinical significance: Target for rituximab therapy
Lost on: Plasma cells (important for therapy resistance)

CD38 - The Plasma Cell Signature

Present on: Plasma cells, activated lymphocytes
Clinical use: Multiple myeloma diagnosis and monitoring

Natural Killer (NK) Cells

CD56 - The NK Identity

Present on: NK cells, some T cells
Function: Innate immunity, tumor surveillance
Clinical relevance: Immunodeficiency evaluation

Myeloid Cells

CD14 - The Monocyte Marker

Present on: Monocytes, macrophages
Clinical use: Acute myeloid leukemia subtyping

CD68 - The Macrophage Signature

Present on: Macrophages, histiocytes
Clinical use: Histiocytic disorders diagnosis

Part 3: Clinical Applications (6 minutes)

Case 1: The Leukemia Diagnosis

Patient: 65-year-old with fatigue, lymphadenopathy Flow cytometry: CD19+, CD20+, CD5+ Diagnosis: Chronic Lymphocytic Leukemia (B-CLL) Key learning: CD5 is normally a T cell marker - when on B cells, think CLL

Case 2: The Immunodeficiency Child

Patient: 2-year-old with recurrent pneumonia Flow cytometry: CD3+ normal, CD4+ very low, CD8+ elevated Diagnosis: DiGeorge syndrome variant Key learning: CD4:CD8 ratio is clinically important

Case 3: The Treatment Decision

Patient: Relapsed B cell lymphoma Pathology: CD20+ lymphoma Treatment: Rituximab (anti-CD20) + chemotherapy Key learning: CD markers guide targeted therapy

Part 4: Practical Tips for Residents (2 minutes)

The "Big 6" to Remember

CD3: All T cells
CD4: Helper T cells (HIV target)
CD8: Killer T cells
CD19: All B cells
CD20: Mature B cells (rituximab target)
CD56: NK cells

Reading Flow Cytometry Reports

Positive (+): Cell expresses the marker
Negative (-): Cell lacks the marker
Dim/Bright: Expression intensity matters
Percentage: What proportion of cells are positive

Clinical Pearl

"When in doubt, remember: CD3 for T cells, CD19/20 for B cells. These three markers will solve 80% of your basic immunophenotyping questions."

Wrap-Up & Take-Home Messages

CD antigens are cellular ID badges that help us classify immune cells
Pattern recognition is key - each cell type has a characteristic CD profile
Clinical relevance spans diagnosis, treatment selection, and monitoring
Start simple - master the basic markers before diving into complex panels
Integration is crucial - always correlate CD findings with clinical presentation

Next Steps

Practice interpreting flow cytometry reports
Review CD markers in your textbook cases
Attend hematopathology rounds to see real examples

Quick Reference Card

T Cells: CD3+ (all), CD4+ (helper), CD8+ (cytotoxic) B Cells: CD19+ (all), CD20+ (mature), CD38+ (plasma cells) NK Cells: CD56+ Monocytes: CD14+

"Master these basics, and you'll navigate 90% of clinical CD antigen scenarios with confidence."

ICU Care in Diphtheria Outbreaks: Managing Airway Obstruction, Myocarditis, and Antitoxin Logistics

ICU Care in Diphtheria Outbreaks: Managing Airway Obstruction, Myocarditis, and Antitoxin Logistics in Resource-Limited Settings

Dr Neeraj Manikath , claude.ai

Abstract

Background: Despite widespread vaccination programs, diphtheria outbreaks continue to pose significant challenges in critical care settings, particularly in developing countries. The resurgence of diphtheria in various regions underscores the need for updated management strategies in intensive care units.

Objective: To provide a comprehensive review of ICU management strategies for diphtheria patients, focusing on airway obstruction, myocarditis, and antitoxin logistics, with special emphasis on resource-limited settings like India.

Methods: Systematic review of literature from 1990-2024, including case series, outbreak reports, and clinical guidelines from WHO, CDC, and regional health authorities.

Results: Modern ICU management of diphtheria requires a multifaceted approach addressing respiratory failure, cardiac complications, and neurological sequelae. Early antitoxin administration, aggressive airway management, and cardiac monitoring are crucial for optimal outcomes.

Conclusions: Despite being a vaccine-preventable disease, diphtheria continues to challenge intensivists, particularly during outbreak situations. Understanding modern management strategies is essential for contemporary critical care practice.

Keywords: Diphtheria, Critical Care, Airway Management, Myocarditis, Antitoxin, Outbreak Management

Introduction

Diphtheria, caused by toxigenic strains of Corynebacterium diphtheriae, remains a significant public health concern despite effective vaccination programs. The disease's clinical manifestations range from mild pharyngeal symptoms to life-threatening respiratory and cardiac complications requiring intensive care management. Recent outbreaks in Yemen (2017-2019), Bangladesh (2017-2018), and sporadic cases in India highlight the continued relevance of this ancient disease in modern medicine.

The pathophysiology of diphtheria is primarily mediated by diphtheria toxin, which inhibits protein synthesis through ADP-ribosylation of elongation factor-2. This mechanism leads to local tissue necrosis, pseudomembrane formation, and systemic toxicity affecting the myocardium, peripheral nerves, and other organs.

Epidemiological Context and Outbreak Dynamics

Global Resurgence Patterns

The World Health Organization reported over 16,000 diphtheria cases globally in 2018, with the highest burden in conflict-affected areas and regions with suboptimal vaccination coverage. In India, despite achieving high routine immunization coverage, sporadic outbreaks continue to occur, particularly in urban slums and remote rural areas.

Clinical Pearl: Suspect diphtheria in any patient with severe pharyngitis and systemic toxicity, especially in areas with suboptimal vaccination coverage or during outbreak situations.

Risk Factors for Severe Disease

Age >40 years or <5 years
Unvaccinated or incompletely vaccinated individuals
Immunocompromised states
Delayed presentation (>72 hours from symptom onset)
Extensive pseudomembrane formation
Bull neck appearance (extensive cervical lymphadenopathy and edema)

Clinical Presentation and ICU Indications

Respiratory Manifestations

The respiratory tract is the most common site of diphtheria infection, with the pharynx and larynx being primarily affected. The characteristic adherent grayish-white pseudomembrane can extend from the soft palate to the larynx, causing varying degrees of airway obstruction.

ICU Admission Criteria:

Respiratory distress or stridor
Bull neck appearance
Signs of systemic toxicity
Cardiac complications
Neurological involvement
Need for antitoxin administration with anaphylaxis risk

Cardiac Complications

Diphtheria myocarditis occurs in 10-25% of cases and is the leading cause of death. It typically manifests 1-6 weeks after initial symptoms, with a biphasic pattern:

Acute phase (1-2 weeks): Conduction abnormalities, arrhythmias
Chronic phase (2-6 weeks): Dilated cardiomyopathy, heart failure

Oyster: The absence of early cardiac symptoms does not exclude myocarditis. Serial ECGs and cardiac biomarkers are essential even in asymptomatic patients.

Airway Management in Diphtheria

Assessment and Monitoring

Airway assessment in diphtheria requires careful evaluation of:

Pseudomembrane extent and adherence
Degree of laryngeal edema
Respiratory effort and oxygen saturation
Voice changes and stridor

Clinical Hack: Use the "hot potato voice" and muffled speech as early indicators of supraglottic involvement, even before visible stridor develops.

Intubation Considerations

Endotracheal intubation in diphtheria patients presents unique challenges:

Difficult intubation: Pseudomembranes can obscure anatomical landmarks
Membrane dislodgement: May cause complete airway obstruction
Bleeding: Friable tissues prone to hemorrhage
Laryngeal edema: May progress rapidly

Intubation Protocol:

Senior anesthesiologist/intensivist should perform
Video laryngoscopy preferred when available
Smaller endotracheal tube (0.5-1.0 mm smaller than calculated)
Surgical airway backup immediately available
Gentle technique to avoid membrane dislodgement

Tracheostomy Indications

Immediate tracheostomy indicated for:

Failed intubation
Extensive laryngeal involvement
Massive cervical lymphadenopathy (bull neck)
Progressive airway obstruction despite medical management

Oyster: In resource-limited settings, early tracheostomy may be preferable to multiple intubation attempts, especially when video laryngoscopy is unavailable.

Non-invasive Ventilation Considerations

NIV is generally contraindicated in diphtheria patients with:

Upper airway obstruction
Risk of aspiration
Hemodynamic instability

However, it may be considered in selected cases with:

Mild respiratory failure
Intact upper airway
Ability to clear secretions

Cardiac Management and Monitoring

Diagnostic Approach

Initial cardiac evaluation should include:

12-lead ECG (repeat every 6-8 hours initially)
Echocardiography
Cardiac biomarkers (Troponin I/T, CK-MB, NT-proBNP)
Chest X-ray

Serial monitoring parameters:

Continuous cardiac rhythm monitoring
Daily ECG for first week, then alternate days
Echocardiography on days 3, 7, 14, and 21
Weekly cardiac biomarkers until normalization

ECG Abnormalities

Common ECG findings in diphtheria myocarditis:

First-degree AV block (most common)
Complete heart block
Bundle branch blocks
ST-T wave changes
Atrial fibrillation
Ventricular arrhythmias

Clinical Pearl: Complete heart block in diphtheria myocarditis may be reversible but can persist for weeks. Temporary pacing should be readily available.

Hemodynamic Management

Heart failure management:

ACE inhibitors/ARBs (if hemodynamically stable)
Beta-blockers (use cautiously, may worsen conduction blocks)
Diuretics for volume overload
Inotropic support if needed (dobutamine preferred)

Arrhythmia management:

Temporary pacing for complete heart block
Amiodarone for ventricular arrhythmias
Avoid digoxin (increased risk of toxicity)

Clinical Hack: In diphtheria myocarditis, intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days may provide additional benefit beyond antitoxin, particularly in severe cases.

Antitoxin Administration and Logistics

Diphtheria Antitoxin (DAT) Overview

Diphtheria antitoxin remains the cornerstone of treatment, neutralizing circulating toxin but not toxin already bound to tissues. Early administration is crucial for optimal outcomes.

Types available:

Equine antitoxin: Most commonly available, higher anaphylaxis risk
Human immunoglobulin: Limited availability, lower adverse reactions

Dosing and Administration

Antitoxin dosing based on clinical severity:

Clinical Presentation	Dose (International Units)	Route
Pharyngeal/Laryngeal	20,000-40,000 IU	IV
Nasopharyngeal	40,000-60,000 IU	IV
Combined/Bull neck	80,000-120,000 IU	IV

Administration protocol:

Skin test (0.1 mL of 1:1000 dilution intradermally)
If positive: Desensitization protocol required
If negative: Direct IV infusion over 4-6 hours
Premedication: Hydrocortisone 100mg IV, Chlorpheniramine 10mg IV

Oyster: A negative skin test does not guarantee absence of anaphylactic reaction. Emergency resuscitation equipment must be immediately available during antitoxin administration.

Logistics in Indian Context

Procurement challenges:

Limited manufacturing (currently only Serum Institute of India)
Cold chain requirements
Batch-to-batch variations in potency
Cost considerations in public health settings

Stock management strategies:

Regional stockpiling in outbreak-prone areas
Rapid distribution networks
Alternative sourcing from international suppliers
Emergency import protocols

Clinical Hack: In antitoxin shortage situations, prioritize administration to patients with respiratory involvement, bull neck, or early cardiac manifestations, as these have the highest mortality risk.

Supportive Care and Complications Management

Respiratory Support

Mechanical ventilation considerations:

Lung-protective strategies (Vt 6-8 mL/kg ideal body weight)
PEEP titration based on compliance and oxygenation
Sedation minimization to preserve respiratory drive
Regular suctioning to clear secretions and membrane fragments

Weaning considerations:

Assess for pseudomembrane reformation
Rule out vocal cord paralysis
Consider tracheostomy for prolonged ventilation

Neurological Complications

Diphtheria neuropathy occurs in 15-20% of cases, typically 2-10 weeks after initial infection:

Early manifestations:

Palatal paralysis (most common)
Oculomotor palsies
Bulbar dysfunction

Late manifestations:

Peripheral neuropathy (ascending pattern)
Respiratory muscle weakness
Autonomic dysfunction

Management approaches:

Supportive care
Physical therapy and rehabilitation
Respiratory support if needed
IVIG may be beneficial in severe cases

Renal and Other Organ Support

Acute kidney injury:

Monitor creatinine and urine output
Avoid nephrotoxic agents
Renal replacement therapy if indicated

Nutritional support:

Early enteral nutrition preferred
Parenteral nutrition if enteral route contraindicated
Monitor for aspiration risk in bulbar involvement

Infection Control and Outbreak Management

Isolation Precautions

Standard precautions:

Contact and droplet precautions until 48 hours after effective antibiotic therapy
Negative pressure rooms preferred for respiratory diphtheria
Healthcare worker protection with appropriate PPE

Antibiotic Therapy

First-line options:

Penicillin G 250,000 IU/kg/day IV (max 2 million IU every 6 hours)
Erythromycin 40-50 mg/kg/day PO/IV (max 2g/day)

Duration: 14 days

Alternative agents:

Clarithromycin, Azithromycin, Lincomycin

Clinical Pearl: Antibiotics do not alter the acute course but prevent transmission and eliminate the carrier state. They should never substitute for antitoxin therapy.

Contact Management

Close contact prophylaxis:

Antibiotic prophylaxis: Erythromycin 40 mg/kg/day × 7 days
Vaccination status assessment and catch-up immunization
Surveillance for 7 days post-exposure

Special Populations and Considerations

Pediatric Considerations

Unique aspects in children:

Higher risk of airway obstruction due to smaller airway caliber
Rapid progression of symptoms
Different antitoxin dosing considerations
Family-centered care approaches during isolation

Pregnancy

Management modifications:

Safe use of penicillin and erythromycin
Antitoxin administration when benefits outweigh risks
Fetal monitoring for maternal hypoxemia
Delivery planning considerations

Immunocompromised Patients

Increased risk factors:

Prolonged bacterial shedding
Atypical presentations
Increased complication rates
Modified vaccine response

Outcome Prediction and Prognostic Factors

Mortality Predictors

Poor prognostic indicators:

Age >40 years or <1 year
Bull neck appearance
Delayed antitoxin administration (>72 hours)
Complete heart block
Respiratory failure requiring mechanical ventilation
Severe myocarditis with hemodynamic compromise

Clinical Hack: The "4-day rule" - mortality increases significantly when antitoxin administration is delayed beyond 4 days from symptom onset.

Scoring Systems

Proposed severity score:

Respiratory involvement: 2 points
Bull neck: 2 points
Cardiac involvement: 3 points
Delayed antitoxin (>72h): 2 points
Age >40 or <5 years: 1 point

Score interpretation:

0-2: Low risk
3-5: Moderate risk
6-10: High risk

Quality Improvement and System Preparedness

ICU Preparedness Checklist

Infrastructure requirements:

Isolation capabilities
Mechanical ventilation capacity
Cardiac monitoring
Emergency airway equipment
Laboratory support for rapid diagnosis

Staff training needs:

Recognition of diphtheria presentations
Airway management techniques
Antitoxin administration protocols
Infection control measures

Performance Indicators

Process indicators:

Time to antitoxin administration
Appropriate isolation implementation
Contact tracing completion rates
Healthcare worker vaccination status

Outcome indicators:

Case fatality rates
Complication rates
Length of ICU stay
Secondary transmission rates

Future Directions and Research Priorities

Emerging Therapies

Investigational approaches:

Human monoclonal antibodies
Novel antitoxin formulations
Immunomodulatory therapies
Extracorporeal toxin removal

Research Gaps

Priority areas:

Optimal antitoxin dosing strategies
Cardiac protection protocols
Neurological complication management
Health economic evaluations

Conclusion

Diphtheria continues to pose significant challenges in critical care settings, particularly during outbreak situations in resource-limited environments. Successful ICU management requires a comprehensive approach addressing airway obstruction, cardiac complications, and systemic toxicity. Early antitoxin administration remains the cornerstone of therapy, while supportive care measures can significantly impact outcomes.

Healthcare systems must maintain preparedness for diphtheria outbreaks through staff training, infrastructure development, and supply chain management. The integration of modern critical care techniques with traditional diphtheria management principles offers the best opportunity for optimal patient outcomes.

As global vaccination coverage faces challenges from vaccine hesitancy and health system disruptions, intensivists must remain vigilant and prepared to manage this ancient disease with modern tools and techniques.

Key Clinical Pearls Summary

Airway Pearl: Early tracheostomy is preferable to multiple intubation attempts in bull neck diphtheria
Cardiac Pearl: Complete heart block may be reversible but can persist for weeks - have temporary pacing ready
Antitoxin Pearl: A negative skin test doesn't guarantee no anaphylaxis - keep resuscitation equipment ready
Timing Pearl: The "4-day rule" - mortality increases significantly with antitoxin delay >4 days
Diagnostic Pearl: Serial ECGs are more valuable than single readings in detecting cardiac involvement

References

World Health Organization. Diphtheria vaccine: WHO position paper. Wkly Epidemiol Rec. 2017;92(31):417-435.
Truelove SA, Keegan LT, Moss WJ, et al. Clinical and epidemiological aspects of diphtheria: a systematic review and pooled analysis. Clin Infect Dis. 2020;71(1):89-97.
Sharma NC, Efstratiou A, Mokrousov I, et al. Diphtheria. Nat Rev Dis Primers. 2019;5(1):81.
Bowman MC, Ballard JD. Diphtheria toxin. Microbiol Spectr. 2019;7(3).
Clarke KEN, MacNeil A, Hadler S, et al. Seroprevalence of diphtheria toxoid antibodies among children and adults in Timorese refugee camps in West Timor. Emerg Infect Dis. 2002;8(10):1081-1085.
Lodeiro-Colatosti A, Ramirez E, Linares M, et al. Diphtheria outbreak in a closed Venezuelan community. Enferm Infecc Microbiol Clin. 2018;36(2):114-116.
Murhekar M, Bitragunta S. Persistence of diphtheria, Hyderabad, India, 2003-2006. Emerg Infect Dis. 2008;14(7):1144-1146.
Singh J, Harit AK, Jain DC, et al. Diphtheria is declining but continues to kill many children: analysis of data from a sentinel centre in Delhi, 1997-2006. Epidemiol Infect. 2009;137(2):204-212.
Pimenta FP, Matias GA, Pereira GA, et al. A PCR for dtxR gene: application in diagnosis of non-toxigenic and toxigenic Corynebacterium diphtheriae. Mol Cell Probes. 2008;22(3):189-192.
Kumar A, Kumar P, Singh SK, et al. Myocarditis due to diphtheria toxin: a case series and review of literature. Ann Trop Paediatr. 2004;24(3):233-240.
McCloskey RV, Green M, Eller JJ, et al. The 1970 epidemic of diphtheria in San Antonio. Ann Intern Med. 1971;75(4):495-503.
Kneen R, Pham NG, Solomon T, et al. Penicillin vs erythromycin in the treatment of diphtheria. Clin Infect Dis. 1998;27(4):845-850.
Kadirova R, Kartoglu HU, Strebel PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz Republic, 1995. J Infect Dis. 2000;181 Suppl 1:S110-115.
Zasada AA. Nontoxigenic highly pathogenic clone of Corynebacterium diphtheriae, Poland, 2004-2012. Emerg Infect Dis. 2013;19(11):1870-1872.
Farizo KM, Strebel PM, Chen RT, et al. Fatal respiratory disease due to Corynebacterium diphtheriae: case report and review of guidelines for management, investigation, and control. Clin Infect Dis. 1993;16(1):59-68.

Fulminant Hepatic Failure in Viral Hepatitis A and E

Fulminant Hepatic Failure in Viral Hepatitis A and E: A Critical Care Perspective for the Tropics

Dr Neeraj Manikath , claude.ai

Abstract

Fulminant hepatic failure (FHF) secondary to hepatitis A virus (HAV) and hepatitis E virus (HEV) infections represents a significant challenge in tropical medicine and critical care. While generally self-limiting, these infections can progress to acute liver failure with high mortality rates, particularly in resource-limited settings where liver transplantation is not readily available. This review examines the pathophysiology, clinical presentation, diagnostic challenges, and management strategies for HAV and HEV-induced FHF, with emphasis on bridging therapies and practical approaches for critical care physicians in tropical regions. We highlight emerging therapeutic options, prognostic indicators, and decision-making frameworks that can optimize outcomes in the absence of transplant facilities.

Keywords: Fulminant hepatic failure, Hepatitis A, Hepatitis E, Critical care, Tropical medicine, Liver transplantation

Introduction

Fulminant hepatic failure (FHF), also termed acute liver failure (ALF), is defined as the rapid development of severe acute liver injury with encephalopathy and impaired synthetic function in a patient without pre-existing liver disease, typically occurring within 26 weeks of symptom onset.¹ In tropical and developing regions, viral hepatitis remains the predominant cause of FHF, with hepatitis A virus (HAV) and hepatitis E virus (HEV) accounting for 60-80% of cases in endemic areas.²,³

The clinical significance of HAV and HEV-induced FHF extends beyond their epidemiological prominence. These infections present unique challenges in critical care management, particularly in resource-constrained settings where liver transplantation—the definitive treatment for FHF—remains largely inaccessible. Understanding the nuanced pathophysiology, recognizing early warning signs, and implementing effective bridging therapies become paramount in improving survival outcomes.

Epidemiology and Risk Factors

Geographic Distribution

HAV and HEV infections demonstrate distinct epidemiological patterns that directly impact FHF incidence. In highly endemic regions (primarily tropical and subtropical areas with poor sanitation), HAV infection typically occurs in early childhood, conferring lifelong immunity and paradoxically reducing FHF rates in adults.⁴ Conversely, improving socioeconomic conditions create populations susceptible to adult HAV infection, increasing FHF risk.

HEV shows more complex epidemiological patterns, with genotype 1 predominating in South and Southeast Asia, genotype 2 in Mexico and Africa, and genotypes 3 and 4 in developed countries.⁵ The tropical burden is primarily from genotypes 1 and 2, which demonstrate higher virulence and greater propensity for FHF development.

High-Risk Populations

Pearl #1: Age-Related Risk Stratification

HAV-induced FHF risk increases exponentially with age >40 years (OR 7.3, 95% CI 3.2-16.7)⁶
HEV-induced FHF shows bimodal distribution: pregnant women (especially third trimester) and immunocompromised patients⁷

Special Populations:

Pregnant Women: HEV infection during pregnancy, particularly in the third trimester, carries a 15-25% mortality rate compared to <1% in non-pregnant women⁸
Immunocompromised Patients: Chronic HEV infection with potential for FHF in solid organ transplant recipients and HIV patients⁹
Pre-existing Liver Disease: Superinfection with HAV or HEV in patients with chronic hepatitis B or C significantly increases FHF risk¹⁰

Pathophysiology

Viral Hepatotrophic Mechanisms

Both HAV and HEV are non-enveloped, single-stranded RNA viruses that primarily target hepatocytes. However, their mechanisms of liver injury differ substantially:

HAV Pathogenesis:

Direct cytopathic effect is minimal
Liver injury primarily mediated by host immune response
CD8+ T-cell activation and cytokine storm (TNF-α, IFN-γ) drive hepatocellular necrosis¹¹
Molecular mimicry may contribute to autoimmune hepatitis-like syndrome

HEV Pathogenesis:

Direct viral cytotoxicity more prominent than HAV
ORF3 protein disrupts cellular signaling pathways
Induces oxidative stress and mitochondrial dysfunction¹²
Pregnancy-associated hormonal changes enhance viral replication and immune dysregulation¹³

Progression to Fulminant Failure

The transition from acute hepatitis to FHF involves multiple interconnected pathways:

Massive Hepatocellular Necrosis: >80% hepatocyte loss within days
Coagulopathy: Decreased synthesis of clotting factors (especially Factor V and VII)
Hepatic Encephalopathy: Accumulation of neurotoxins (ammonia, aromatic amino acids, benzodiazepine-like compounds)
Multi-organ Dysfunction: Renal failure, cardiovascular instability, immune dysfunction

Hack #1: Early Recognition Pattern Monitor the "Rule of 3s" for FHF progression:

ALT >3000 IU/L with rapid decline
INR >3.0 with Factor V <30%
Grade 3+ encephalopathy within 72 hours

Clinical Presentation and Diagnosis

Clinical Phases

Phase 1: Prodromal (1-7 days)

Constitutional symptoms: fatigue, nausea, vomiting, abdominal pain
Often indistinguishable from other viral illnesses
Oyster Alert: Absence of jaundice in 10-15% of HAV cases and up to 30% of HEV cases¹⁴

Phase 2: Hepatic (7-14 days)

Jaundice, hepatomegaly, right upper quadrant tenderness
Laboratory evidence of hepatocellular injury
Pearl #2: Rapid normalization of ALT/AST in setting of worsening synthetic function suggests massive hepatocyte loss, not recovery

Phase 3: Recovery or Fulminant Progression (14-28 days)

Either gradual improvement or rapid deterioration to FHF
Encephalopathy development marks transition to FHF

Diagnostic Approach

Laboratory Markers:

HAV: Anti-HAV IgM (sensitivity >95% during acute phase)
HEV: Anti-HEV IgM and HEV RNA (IgM may be negative in immunocompromised patients)¹⁵

Prognostic Indicators:

Pearl #3: Modified King's College Criteria for Viral Hepatitis Poor prognosis indicated by:

pH <7.30 (or lactate >3.0 mmol/L if pH unavailable)
AND Grade 3-4 encephalopathy
AND INR >6.5 (or PT >100 seconds)¹⁶

Hack #2: Tropical-Specific Prognostic Score Develop local scoring systems incorporating:

MELD-Na score >30
Ammonia level >150 μmol/L
Neutrophil-lymphocyte ratio >8
Serum phosphate <0.4 mmol/L¹⁷

Management Strategies

General Supportive Care

Hemodynamic Management:

Central venous access for monitoring and drug administration
Maintain MAP >65 mmHg with judicious fluid resuscitation
Pearl #4: Avoid excessive fluid administration; hepatorenal syndrome risk increases with positive fluid balance >3L¹⁸

Neurological Monitoring:

Serial Glasgow Coma Scale assessment
ICP monitoring in Grade 3-4 encephalopathy (if available)
Hack #3: Pupillary response and oculocephalic reflexes are reliable ICP surrogates when direct monitoring unavailable¹⁹

Specific Interventions

Coagulopathy Management:

Pearl #5: Avoid prophylactic FFP/platelets unless active bleeding or invasive procedures planned (masks prognostic indicators)
Vitamin K 10mg IV daily for 3 days
Consider PCC (prothrombin complex concentrate) for urgent procedures²⁰

Hepatic Encephalopathy:

Lactulose 30-45ml q6h (target 2-3 soft stools/day)
Rifaximin 400mg TID if available and affordable
Hack #4: Zinc supplementation (50mg daily) may accelerate ammonia metabolism²¹

Renal Protection:

Avoid nephrotoxic drugs
Maintain euvolemia
Early CRRT initiation for fluid overload or severe metabolic acidosis
Pearl #6: Terlipressin 1-2mg q4-6h may prevent/reverse hepatorenal syndrome²²

Bridging Therapies in Resource-Limited Settings

Molecular Adsorbent Recirculating System (MARS):

Limited availability but can bridge 7-14 days
Reduces ammonia, bilirubin, and inflammatory mediators
Consider if transplant evaluation possible within 2 weeks²³

Plasma Exchange (PLEX):

More widely available alternative to MARS
Remove toxins and replace clotting factors simultaneously
Protocol: 1.0-1.5 plasma volumes daily for 3-5 days²⁴
Pearl #7: Monitor fibrinogen levels closely; severe hypofibrinogenemia indicates need to reduce exchange volume

Albumin Dialysis (SPAD):

Single-pass albumin dialysis using standard CRRT machines
More cost-effective than MARS in resource-limited settings
Hack #5: 4% albumin solution in dialysate can achieve similar toxin removal at 1/3 the cost²⁵

High-Volume Continuous Hemofiltration:

Enhanced cytokine removal with filtration rates >35mL/kg/hr
May reduce systemic inflammatory response
Monitor electrolyte losses carefully²⁶

Novel and Emerging Therapies

N-Acetylcysteine (NAC):

Not limited to acetaminophen poisoning
Protocol: 150mg/kg IV over 1hr, then 12.5mg/kg/hr continuous infusion
Improves oxygen delivery and may enhance spontaneous recovery in viral hepatitis²⁷

Corticosteroids:

Controversial: Some benefit in HAV-induced FHF with significant inflammatory component
Consider prednisolone 1mg/kg daily for 5-7 days if no contraindications
Oyster Alert: May worsen HEV infection, especially in pregnancy²⁸

Hepatocyte Growth Factor:

Promotes hepatocyte regeneration
Limited availability but promising results in pilot studies²⁹

Transplant Considerations and Limitations

Transplant Criteria

Absolute Indications:

Grade 3-4 encephalopathy with King's College Criteria
Severe metabolic acidosis (pH <7.25) unresponsive to bicarbonate
Refractory hypoglycemia despite continuous glucose infusion

Relative Contraindications in Tropical Settings:

Age >65 years (limited organ availability)
Multiple organ failure with SOFA score >15
Sepsis with multidrug-resistant organisms³⁰

Resource Limitations

Infrastructure Challenges:

Limited transplant centers (often <1 per 10 million population)
Organ procurement and allocation systems underdeveloped
High costs (USD $150,000-300,000) prohibitive for most patients

Hack #6: Transplant Decision Algorithm for Resource-Limited Settings

Day 1-3: Aggressive supportive care and bridging therapies
Day 4-7: If no improvement and transplant potentially available, initiate evaluation
Day 8-14: Continue bridging; consider experimental therapies
Day 15+: Focus on comfort care if no transplant option and continued deterioration

Prognostic Indicators and Outcome Predictors

Traditional Scoring Systems

MELD-Na Score:

Most widely validated in tropical populations
Score >30 predicts 90-day mortality >50%
Pearl #8: Add extra points for encephalopathy grade (Grade 3 = +6, Grade 4 = +10)³¹

APACHE II Score:

General ICU mortality predictor
Scores >20 suggest poor prognosis in viral hepatitis FHF

Novel Biomarkers

Alpha-Fetoprotein (AFP):

Rising levels (>100 ng/mL daily increase) suggest hepatic regeneration
Pearl #9: AFP doubling time <7 days associated with survival without transplant³²

Serum Phosphate:

Severe hypophosphatemia (<0.4 mmol/L) predicts poor outcome
Reflects impaired hepatic ATP synthesis
Hack #7: Phosphate replacement should target levels >0.8 mmol/L³³

Arterial Lactate:

More readily available than arterial pH
Lactate >3.5 mmol/L equivalent to pH <7.30 for prognostic purposes
Serial measurements more valuable than single values³⁴

Special Considerations

Pregnancy and HEV

Management Pearls:

Pearl #10: Delivery does not improve maternal outcome in HEV-induced FHF and may worsen coagulopathy
Fetal monitoring essential; emergency delivery if fetal distress
Consider early delivery only if maternal condition stabilizes
Avoid breastfeeding until HEV RNA negative³⁵

Pediatric Considerations

Age-Specific Differences:

Better regenerative capacity but higher risk of cerebral edema
Lower threshold for invasive monitoring
Adjust drug dosing for hepatic impairment more conservatively³⁶

Resource Allocation

Triage Considerations:

Prioritize patients with single organ failure (liver only)
Consider social support systems for long-term recovery
Ethical Framework: Transparent criteria for ICU admission and bridging therapy allocation³⁷

Prevention Strategies

Primary Prevention

HAV Vaccination:

Cost-effective in transitional epidemiological settings
Two-dose schedule (0, 6-12 months)
Consider catch-up vaccination for adults >40 years in improving sanitation areas⁴

HEV Prevention:

No globally available vaccine (HEV 239 available only in China)
Focus on sanitation improvement and safe water access
Pregnant women counseling in endemic areas⁸

Secondary Prevention

Post-Exposure Prophylaxis:

HAV: Immunoglobulin within 2 weeks of exposure
HEV: No effective post-exposure prophylaxis available

Quality Improvement and System-Level Interventions

Clinical Protocols

Hack #8: Standardized FHF Protocol

Early recognition criteria and escalation pathways
Standardized laboratory monitoring schedules
Clear triggers for specialty consultation and transfer
Family communication protocols³⁸

Training and Education

Competency Requirements:

Recognition of early FHF signs in viral hepatitis
Proficiency in bridging therapies
Understanding of transplant referral criteria
Prognostic counseling skills

Research Priorities

Clinical Research Needs:

Validation of prognostic scores in tropical populations
Cost-effectiveness analysis of bridging therapies
Optimal timing and patient selection for interventions
Development of point-of-care prognostic biomarkers³⁹

Future Directions

Therapeutic Innovations

Bioartificial Liver Systems:

Hepatocyte-based systems showing promise in clinical trials
May become more feasible than transplantation in resource-limited settings⁴⁰

Stem Cell Therapy:

Mesenchymal stem cells for hepatic regeneration
Potential for autologous cell therapy protocols⁴¹

Gene Therapy:

Hepatocyte growth factor gene delivery
CRISPR-based approaches for viral clearance⁴²

System Improvements

Telemedicine Integration:

Remote consultation for transplant evaluation
AI-assisted prognostic algorithms
Mobile health platforms for follow-up⁴³

Conclusion

Fulminant hepatic failure secondary to HAV and HEV infections represents a critical challenge in tropical medicine, requiring sophisticated critical care management in settings where definitive therapy (liver transplantation) is often unavailable. Success depends on early recognition, aggressive supportive care, judicious use of bridging therapies, and realistic prognostic assessment.

The key to improving outcomes lies in developing systematic approaches that optimize available resources while maintaining hope for recovery. Critical care physicians must balance aggressive intervention with appropriate palliation, always considering the social and economic context of their patients. As bridging therapies evolve and become more accessible, the window for spontaneous recovery may expand, making the management of these patients increasingly rewarding.

Future research should focus on developing cost-effective interventions, validating prognostic tools in diverse populations, and creating sustainable systems of care that can deliver optimal outcomes regardless of transplant availability. The goal is not merely to replicate Western critical care models but to innovate solutions appropriate for tropical and resource-limited settings while maintaining the highest standards of medical care.

Take-Home Messages:

Age >40 years significantly increases FHF risk in HAV infection
Pregnancy triples HEV-related mortality risk
Avoid prophylactic blood product transfusion unless actively bleeding
MARS/PLEX can provide effective bridging for 1-2 weeks
Rising AFP and improving phosphate levels predict spontaneous recovery
Transplant evaluation should begin by day 4-7 if criteria met
Focus on systems-based approaches and realistic resource allocation

References

Lee WM, Larson AM, Stravitz RT. AASLD Position Paper: The management of acute liver failure: update 2011. Hepatology. 2011;55(3):965-967.
Khuroo MS, Kamili S. Aetiology and prognostic factors in acute liver failure in India. J Viral Hepat. 2003;10(3):224-231.
Shalimar, Acharya SK. Hepatitis E and acute liver failure in pregnancy. J Clin Exp Hepatol. 2013;3(3):213-224.
Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28(41):6653-6657.
Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014;27(1):116-138.
Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338(5):286-290.
Kumar A, Aggarwal R, Naik SR, et al. Hepatitis E virus is responsible for decompensation of chronic liver disease in an endemic region. Indian J Gastroenterol. 2004;23(2):59-62.
Patra S, Kumar A, Trivedi SS, et al. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med. 2007;147(1):28-33.
Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811-817.
Vento S, Cainelli F, Renzini C, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 1996;347(9009):92-93.
Maier K, Faulstich H, Gerbes AL. The role of T-lymphocytes in hepatitis A virus infection. Hepatology. 1988;8(5):1132-1136.
Moin SM, Chandra V, Arya R, et al. Hepatitis E virus pathogenesis: current understanding and future perspectives. Virus Res. 2009;144(1-2):1-12.
Navaneethan U, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int. 2008;28(9):1190-1199.
Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995;90(2):201-205.
Aggarwal R, Naik S. Epidemiology of hepatitis E: current status. J Gastroenterol Hepatol. 2009;24(9):1484-1493.
O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445.
Kumar R, Shalimar, Bhatia V, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51(5):1665-1674.
Cardoso FS, Gottfried M, Tujios S, et al. Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure. Hepatology. 2018;67(2):711-720.
Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11(12):1581-1589.
Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007;35(11):2498-2508.
Mohamad Yusoff F, Mohamed R, Lau SH, et al. Zinc supplementation in chronic hepatitis C patients is associated with decreased serum alanine aminotransferase activity. J Gastroenterol Hepatol. 2012;27(8):1317-1322.
Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310-1318.
Hassanein TI, Tofteng F, Brown RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46(6):1853-1862.
Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol. 2016;64(1):69-78.
Sauer IM, Goetz M, Steffen I, et al. In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology. 2004;39(5):1408-1414.
Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038-1047.
Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864.
Dalton HR, Kamar N, Baylis SA, et al. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68(6):1256-1271.
Kosai K, Matsumoto K, Funakoshi H, et al. Hepatocyte growth factor prevents endotoxin-induced lethal hepatic failure in mice. Hepatology. 1999;30(1):151-159.
Piano S, Brocca A, Mareso S, et al. Infections complicating cirrhosis. Liver Int. 2018;38 Suppl 1:126-133.
Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-470.
Schiødt FV, Ostapowicz G, Murray N, et al. Alpha-fetoprotein and prognosis in acute liver failure. Liver Transpl. 2006;12(12):1776-1781.
Antoniades CG, Berry PA, Davies ET, et al. Reduced hepatic glutamine synthetase activity in patients with hepatic encephalopathy. Gut. 2009;58(10):1393-1398.
Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet. 2002;359(9306):558-563.
Kumar A, Beniwal M, Kar P, et al. Hepatitis E in pregnancy. Int J Gynaecol Obstet. 2004;85(3):240-244.
Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr. 2006;148(5):652-658.
Wendon J, Cordoba J, Dhawan A, et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-1081.
Reuben A, Tillman H, Fontana RJ, et al. Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study. Ann Intern Med. 2016;164(11):724-732.
Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525-2534.
Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004;239(5):660-667.
Kuo TK, Hung SP, Chuang CH, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134(7):2111-2121.
Pan Q, Ramakrishnaiah V, Henry S, et al. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut. 2012;61(9):1330-1339.
Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108(9):1458-1463.